Publications

2025

• Hepatoblastoma: Comprehensive Review With Recent Updates.Jiao J, Saxena R, Morotti R. Hepatoblastoma: Comprehensive Review With Recent Updates. Adv Anat Pathol 2025 PMID: 40178831, DOI: 10.1097/PAP.0000000000000495.
• An in vivo screen identifies NAT10 as a master regulator of brain metastasis.Chen JF, Xu P, Cai WL, Chen H, Wingrove E, Shi X, Li W, Biancon G, Zhang M, Balabaki A, Krop ED, Asare E, Zhang Y, Yin M, Tebaldi T, Meier JL, Westbrook TF, Halene S, Liu Y, Shen H, Nguyen DX, Yan Q. An in vivo screen identifies NAT10 as a master regulator of brain metastasis. Sci Adv 2025, 11: eads6021. PMID: 40138393, DOI: 10.1126/sciadv.ads6021.

  
• Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementBorate U, Pugh K, Waller A, Welkie R, Huang Y, Bewersdorf J, Stahl M, DeZern A, Platzbecker U, Sekeres M, Wei A, Buckstein R, Roboz G, Savona M, Loghavi S, Hasserjian R, Fenaux P, Sallman D, Hourigan C, Della Porta M, Nimer S, Little R, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim T, Halene S, Komrokji R, Griffiths E, Greenberg P, Xu M, Xie Z, Bejar R, Sanz G, Patnaik M, Figueroa M, Carraway H, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver N, Churpek J, Majeti R, Bennett J, List A, Brunner A, Zeidan A. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood 2025, 145: 1369-1381. PMID: 40146152, DOI: 10.1182/blood.2023023717.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patientsMack P, Crawford J, Chang A, Yin A, Klein S, Shea P, Hirsch F, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove J, Halene S, Lee F, Mantis N, Kushi L, Weiskopf D, Merchant A, Reckamp K, Skarbinski J, Figueiredo J. In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients. Journal Of The National Cancer Institute 2025, djaf073. PMID: 40127178, DOI: 10.1093/jnci/djaf073.

  
• Spatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planusKidacki M, Cho C, Lopez-Giraldez F, Breidbart R, Jaiswal A, Lee M, Chowdhury S, Damsky W, Chen L, Vesely M. Spatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planus. Journal Of Investigative Dermatology 2025 PMID: 40113031, DOI: 10.1016/j.jid.2025.02.148.

  
• IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer.Ranjan K, Rajendran BK, Deen IU, Costantini A, de Rodas ML, Desai SS, Scallo F, Gianino N, Ferrone S, Schalper KA. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Mol Cancer 2025, 24: 80. PMID: 40091029, DOI: 10.1186/s12943-025-02276-z.

  
• The neuropathologic basis for translational biomarker development in the macaque model of late-onset Alzheimer's disease.Zeiss C, Huttner A, Nairn A, Arnsten A, Datta D, Strittmatter S, Wyk B, Duque A. The neuropathologic basis for translational biomarker development in the macaque model of late-onset Alzheimer's disease. Journal Of Alzheimer's Disease 2025, 13872877251323787. PMID: 40095666, DOI: 10.1177/13872877251323787.
• Correction: EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repairKoyen A, Madden M, Park D, Minten E, Kapoor-Vazirani P, Werner E, Pfister N, Haji-Seyed-Javadi R, Zhang H, Xu J, Deng N, Duong D, Pecen T, Frazier Z, Nagel Z, Lazaro J, Mouw K, Seyfried N, Moreno C, Owonikoko T, Deng X, Yu D. Correction: EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene 2025, 44: 928-930. PMID: 40097809, DOI: 10.1038/s41388-025-03345-9.
• BCL2 inhibition for multiple myeloma and AL amyloidosisCani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025 PMID: 40090369, DOI: 10.1111/bjh.20046.

  
• Subcellular proteomics and iPSC modeling uncover reversible mechanisms of axonal pathology in Alzheimer’s diseaseCai Y, Kanyo J, Wilson R, Bathla S, Cardozo P, Tong L, Qin S, Fuentes L, Pinheiro-de-Sousa I, Huynh T, Sun L, Mansuri M, Tian Z, Gan H, Braker A, Trinh H, Huttner A, Lam T, Petsalaki E, Brennand K, Nairn A, Grutzendler J. Subcellular proteomics and iPSC modeling uncover reversible mechanisms of axonal pathology in Alzheimer’s disease. Nature Aging 2025, 5: 504-527. PMID: 40065072, PMCID: PMC11922768, DOI: 10.1038/s43587-025-00823-3.

  
• Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trialZerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm D, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. Npj Breast Cancer 2025, 11: 23. PMID: 40055382, DOI: 10.1038/s41523-025-00730-1.

  
• An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesisEl Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E, Kramer N, Bourilhon P, Kontos C, Zarwel M, Sinitski D, Milic J, Jansen Y, Kempf W, Sachs N, Maegdefessel L, Ji H, Gokce O, Riols F, Haid M, Gerra S, Hoffmann A, Brandhofer M, Avdic M, Bucala R, Megens R, Willemsen N, Messerer D, Schulz C, Bartelt A, Harm T, Rath D, Döring Y, Gawaz M, Weber C, Kapurniotu A, Bernhagen J. An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis. Nature Communications 2025, 16: 2297. PMID: 40055309, DOI: 10.1038/s41467-025-57540-z.

  
• Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025 PMID: 40047548, DOI: 10.1158/1078-0432.ccr-24-3347.

  
• Associations between Blood DNA Methylation and Histopathological Features in Lupus Nephritis.Demkowicz P, Kavaliauskaite I, Faulkner S, Kent C, Shaw M, Kumar D, Ix J, Wilson F, Moledina D, Bakhoum M, Bakhoum C. Associations between Blood DNA Methylation and Histopathological Features in Lupus Nephritis. Kidney360 2025 PMID: 40048255, DOI: 10.34067/kid.0000000758.

  
• A single-cell atlas of circulating immune cells over the first 2 months of age in extremely premature infantsOlaloye O, Gu W, Gehlhaar A, Sabuwala B, Eke C, Li Y, Kehoe T, Farmer R, Gabernet G, Lucas C, Tsang J, Lakhani S, Taylor S, Tseng G, Kleinstein S, Konnikova L. A single-cell atlas of circulating immune cells over the first 2 months of age in extremely premature infants. Science Translational Medicine 2025, 17: eadr0942. PMID: 40043141, DOI: 10.1126/scitranslmed.adr0942.

  
• Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient populationArun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.
• Hypercholesterolemia-induced LXR signaling in smooth muscle cells contributes to vascular lesion remodeling and visceral functionZhang H, de Urturi D, Fernández-Tussy P, Huang Y, Jovin D, Zhang X, Huang S, Lek M, da Silva Catarino J, Sternak M, Citrin K, Swirski F, Gustafsson J, Greif D, Esplugues E, Biwer L, Suárez Y, Fernández-Hernando C. Hypercholesterolemia-induced LXR signaling in smooth muscle cells contributes to vascular lesion remodeling and visceral function. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2417512122. PMID: 40035761, PMCID: PMC11912459, DOI: 10.1073/pnas.2417512122.

  
• Morphological alterations of the thymus gland in individuals with schizophreniaZhao Q, Wei X, Yu W, Li X, Gao Z, Liu S, Liu Z, Wang K, Bishop J, Hu H, Luo C, Xiao Y, Hu N, Tao B, Zhu F, Gong Q, Lui S. Morphological alterations of the thymus gland in individuals with schizophrenia. Molecular Psychiatry 2025, 1-11. PMID: 40038543, DOI: 10.1038/s41380-025-02946-w.
• Drugging Disordered Proteins by Conformational Selection to Inform Therapeutic InterventionBogin B, Levine Z. Drugging Disordered Proteins by Conformational Selection to Inform Therapeutic Intervention. Journal Of Chemical Theory And Computation 2025, 21: 3204-3215. PMID: 40029731, DOI: 10.1021/acs.jctc.4c01160.

  
• Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidanceJiang W, Gan D, Johnson M, Latich I, Lee F. Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance. EngMedicine 2025, 2: 100051. DOI: 10.1016/j.engmed.2024.100051.
• 110 Characterization of Frequency and Spectrum of PIK3CA Somatic Mutations in Advanced Breast CancerAmraei R, Kahn A, Walther Z, Finberg K, Gibson J, Kahila M. 110 Characterization of Frequency and Spectrum of PIK3CA Somatic Mutations in Advanced Breast Cancer. Laboratory Investigation 2025, 105: 102334. DOI: 10.1016/j.labinv.2024.102334.
• 1035 Pathological and Molecular Signatures of De-differentiated Endometrial Carcinomas- An Institutional Study of 52 CasesArbelaez C, Babb P, Sun T, Buza N, Hui P. 1035 Pathological and Molecular Signatures of De-differentiated Endometrial Carcinomas- An Institutional Study of 52 Cases. Laboratory Investigation 2025, 105: 103269. DOI: 10.1016/j.labinv.2024.103269.
• 1044 Discordant HER2 Scores in Endometrial Cancer Using Endometrial versus Gastric Criteria: Implications for treatment eligibilityMoscona A, Babb P, Rottmann D, Sun T, Hui P, Buza N. 1044 Discordant HER2 Scores in Endometrial Cancer Using Endometrial versus Gastric Criteria: Implications for treatment eligibility. Laboratory Investigation 2025, 105: 103278. DOI: 10.1016/j.labinv.2024.103278.
• Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinomaSu D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.
• Response and Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative NeoplasmsGoldberg L, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Cursio J, Patel A. Response and Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms. Blood Neoplasia 2025, 100089. DOI: 10.1016/j.bneo.2025.100089.

  
• 340 Cytomorphologic Challenges in Cervical Pap Tests of Transgender Men on Androgen Therapy: A Cyto-Histological Correlation StudyHaque M, Amraei R, Iyer K, Krishnamurti U, Adeniran A, Sun T. 340 Cytomorphologic Challenges in Cervical Pap Tests of Transgender Men on Androgen Therapy: A Cyto-Histological Correlation Study. Laboratory Investigation 2025, 105: 102567. DOI: 10.1016/j.labinv.2024.102567.
• 711 Gastric Adenocarcinoma in Autoimmune Atrophic Gastritis: Clinicopathologic Study of 18 Cases with Focus on Pyloric Gland Type AdenocarcinomaWang X, Jiao J, Huh W, Zhang X. 711 Gastric Adenocarcinoma in Autoimmune Atrophic Gastritis: Clinicopathologic Study of 18 Cases with Focus on Pyloric Gland Type Adenocarcinoma. Laboratory Investigation 2025, 105: 102942. DOI: 10.1016/j.labinv.2024.102942.
• 604 Whole Exome Sequencing Reveals Genetic Alterations Involving MEN1 as a Potential Mechanism of Wnt Signaling Activation in Gastric Adenocarcinoma of the Fundic Gland TypeHuh W, Bearse M, Finberg K, Jain D. 604 Whole Exome Sequencing Reveals Genetic Alterations Involving MEN1 as a Potential Mechanism of Wnt Signaling Activation in Gastric Adenocarcinoma of the Fundic Gland Type. Laboratory Investigation 2025, 105: 102835. DOI: 10.1016/j.labinv.2024.102835.
• 315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle AspirationBernhisel A, Sun T, Prasad M, Ladenheim A, Cai G, Adeniran A. 315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration. Laboratory Investigation 2025, 105: 102542. DOI: 10.1016/j.labinv.2024.102542.
• 411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studiesYu S, Wang M, Langdon J, Sinard J, Cai G, Prasad M, Adeniran A. 411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies. Laboratory Investigation 2025, 105: 102638. DOI: 10.1016/j.labinv.2024.102638.
• 542 Clinicopathologic Features of Thyroid Nodules with BRAF non-V600E MutationsVerma A, Cedeño E, Abi-Raad R, Ladenheim A, Prasad M. 542 Clinicopathologic Features of Thyroid Nodules with BRAF non-V600E Mutations. Laboratory Investigation 2025, 105: 102772. DOI: 10.1016/j.labinv.2024.102772.
• 401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort StudyWang M, Abi-Raad R, Krishnamurti U, Cai G, Adeniran A, Sun T. 401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort Study. Laboratory Investigation 2025, 105: 102628. DOI: 10.1016/j.labinv.2024.102628.
• 351 Follicular Neoplasms: Cytomorphological Subclassification, Molecular Alterations and Risk of MalignancyKaur H, Gereg C, Abi-Raad R, Adeniran A, Cai G. 351 Follicular Neoplasms: Cytomorphological Subclassification, Molecular Alterations and Risk of Malignancy. Laboratory Investigation 2025, 105: 102578. DOI: 10.1016/j.labinv.2024.102578.
• 334 Utility of SATB2 Immunocytochemistry in the Diagnostic Workup of Cytological Specimens from Patients with Suspected OsteosarcomaGereg C, Cai G. 334 Utility of SATB2 Immunocytochemistry in the Diagnostic Workup of Cytological Specimens from Patients with Suspected Osteosarcoma. Laboratory Investigation 2025, 105: 102561. DOI: 10.1016/j.labinv.2024.102561.
• 341 Comparative Assessment of Claudin-4, MOC-31, and BerEP4 Immunomarkers in Diagnostic Workup of Metastatic Carcinoma in Serous Fluid SpecimensHaque M, Kaur H, Wang M, Cai G. 341 Comparative Assessment of Claudin-4, MOC-31, and BerEP4 Immunomarkers in Diagnostic Workup of Metastatic Carcinoma in Serous Fluid Specimens. Laboratory Investigation 2025, 105: 102568. DOI: 10.1016/j.labinv.2024.102568.
• 116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast CancerBabb P, Theriot J, Liang Y, Cartagena L, Buza N, Krishnamurti U, Zhan H. 116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer. Laboratory Investigation 2025, 105: 102340. DOI: 10.1016/j.labinv.2024.102340.
• 213 Focal Atypical Ductal Hyperplasia (ADH) Upgrade Rate with Radiological Correlation: A Single Institution StudyPodany P, Kahila M, Proussaloglou E, Lewin J, Andrejeva L, Krishnamurti U. 213 Focal Atypical Ductal Hyperplasia (ADH) Upgrade Rate with Radiological Correlation: A Single Institution Study. Laboratory Investigation 2025, 105: 102437. DOI: 10.1016/j.labinv.2024.102437.
• 270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast CancersZhan H, Chan N, Rimm D. 270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast Cancers. Laboratory Investigation 2025, 105: 102494. DOI: 10.1016/j.labinv.2024.102494.
• 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer PatientsChan N, Gaule P, Benanto J, Robbins C, Scott L, Hill S, Morrison R, Liebler D, Fulton R, Rimm D. 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients. Laboratory Investigation 2025, 105: 102351. DOI: 10.1016/j.labinv.2024.102351.
• 119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic MeasurementsBates K, Fernandez A, Martinez-Morilla S, Chan N, Benanto J, Reisenbichler E, Rimm D. 119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements. Laboratory Investigation 2025, 105: 102343. DOI: 10.1016/j.labinv.2024.102343.
• 214 Histologic Analysis and Clinical Correlation of Atypical Apocrine LesionsPodany P, Zhan H, Cartagena L, Krishnamurti U, Liang Y. 214 Histologic Analysis and Clinical Correlation of Atypical Apocrine Lesions. Laboratory Investigation 2025, 105: 102438. DOI: 10.1016/j.labinv.2024.102438.
• 437 Spatial Whole Transcriptomic Analysis Reveals Differential Gene Expression in Epithelial and Mesenchymal Components of Primary Cutaneous CarcinosarcomasHernandez S, Galan A, Lu W, Lermi N, Aung P, Kostousov L, Barnes S, Khan K, Chen K, Soto L, Nagarajan P. 437 Spatial Whole Transcriptomic Analysis Reveals Differential Gene Expression in Epithelial and Mesenchymal Components of Primary Cutaneous Carcinosarcomas. Laboratory Investigation 2025, 105: 102665. DOI: 10.1016/j.labinv.2024.102665.
• 487 Proof of Concept: Facilitating Millennials' Engagement and Actionable Education in Dermatopathology Through an International Online EventErem A, Xavier J, Galan A, Lee J. 487 Proof of Concept: Facilitating Millennials' Engagement and Actionable Education in Dermatopathology Through an International Online Event. Laboratory Investigation 2025, 105: 102716. DOI: 10.1016/j.labinv.2024.102716.
• DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMAKashima S, Gupta R, Moritz V, Sadak K, Walker J, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMA. Urologic Oncology Seminars And Original Investigations 2025, 43: 22-23. DOI: 10.1016/j.urolonc.2024.12.057.
• 831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trialLaimon Y, Paul M, Jammihal T, Ghandour F, Ahmar N, Simsek B, Matar S, Denize T, Mohanna R, De Oliveira G, Delcea A, Shukla S, Braun D, Sun M, Aftab D, Saad E, Machaalani M, Xie W, Choueiri T, Signoretti S. 831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial. Laboratory Investigation 2025, 105: 103064. DOI: 10.1016/j.labinv.2024.103064.
• 796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical TrialAhmar N, Simsek B, Jegede O, Matar S, Savla V, Laimon Y, Mohanna R, De Oliveira G, Sheshdeh A, Delcea A, Paul M, Choueiri T, Xie W, Freeman G, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. 796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical Trial. Laboratory Investigation 2025, 105: 103029. DOI: 10.1016/j.labinv.2024.103029.
• 129 Unmasking Adenomyoepithelial Lesions of the Breast: A Review of 29 CasesCartagena L, Liang Y, Zhan H, Krishnamurti U. 129 Unmasking Adenomyoepithelial Lesions of the Breast: A Review of 29 Cases. Laboratory Investigation 2025, 105: 102353. DOI: 10.1016/j.labinv.2024.102353.
• EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIESRahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.
• Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acidPan M, Zhang Y, Wright W, Liu X, Passaia B, Currier D, Low J, Chapple R, Steele J, Connelly J, Ju B, Plyler E, Lu M, Loughran A, Yang L, Abraham B, Pruett-Miller S, Freeman B, Campbell G, Dyer M, Chen T, Stewart E, Koo S, Sheppard H, Easton J, Geeleher P. Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid. Nature Communications 2025, 16: 2036. PMID: 40021625, PMCID: PMC11871043, DOI: 10.1038/s41467-025-57185-y.

  
• Generation of Orthogonal Gradients of the Matrix Stiffness and Chemotactic Cues in a Suspended Array of Hydrogel to Study hMSCs MigrationXu Z, Ponek A, Thomas J, Qyang Y. Generation of Orthogonal Gradients of the Matrix Stiffness and Chemotactic Cues in a Suspended Array of Hydrogel to Study hMSCs Migration. ACS Sensors 2025, 10: 1722-1728. PMID: 40021359, DOI: 10.1021/acssensors.4c02793.
• Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsSkoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, Le J, Montesion M, Palmer R, Jahchan N, Juan J, Min C, Yu Y, Pan X, Arbour K, Vokes N, Schmidt S, Molkentine D, Owen D, Memmott R, Patil P, Marmarelis M, Awad M, Murray J, Hellyer J, Gainor J, Dimou A, Bestvina C, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian M, Sacher A, Lau S, Saltos A, Rotow J, Johnson R, Liu C, Stewart T, Goldberg S, Killam J, Walther Z, Schalper K, Davies K, Woodcock M, Anagnostou V, Marrone K, Forde P, Ricciuti B, Venkatraman D, Van Allen E, Cummings A, Goldman J, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok J, Segal J, Ritterhouse L, Neal J, Lacroix L, Elamin Y, Negrao M, Le X, Lam V, Lewis W, Kemp H, Carter B, Roth J, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula A, Parra Cuentas E, Behrens C, Wistuba I, Zhang J, Blumenschein G, Gay C, Byers L, Gibbons D, Tsao A, Lee J, Bivona T, Camidge D, Gray J, Leighl N, Levy B, Brahmer J, Garassino M, Gandara D, Garon E, Rizvi N, Scagliotti G, Wolf J, Planchard D, Besse B, Herbst R, Wakelee H, Pennell N, Shaw A, Jänne P, Carbone D, Hellmann M, Rudin C, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson M, Wong K, Huang A, Winslow M, Rosen M, Winters I, Papadimitrakopoulou V, Cascone T, Jewsbury P, Heymach J. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2025, 639: e19-e19. PMID: 40016449, PMCID: PMC11903295, DOI: 10.1038/s41586-025-08767-9.

  
• Bisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinomaYang Z, Chen Q, Dong S, Xu P, Mao Z, Dong Y, Li W, Li W, Han Y, Dai L, Dong G, Zhang Y, Li Y, Cheng L, Ci W, Yu W, Xu C. Bisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma. Bioengineering & Translational Medicine 2025 DOI: 10.1002/btm2.70004.
• Longitudinal CNS and systemic T-lymphocyte and monocyte activation before and after antiretroviral therapy beginning in primary HIV infectionChan P, Li X, Li F, Emu B, Price R, Spudich S. Longitudinal CNS and systemic T-lymphocyte and monocyte activation before and after antiretroviral therapy beginning in primary HIV infection. Frontiers In Immunology 2025, 16: 1531828. PMID: 40070827, PMCID: PMC11893981, DOI: 10.3389/fimmu.2025.1531828.

  
• HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapyJiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, Nabilsi N, Kramer N, Forman C, Lippincott I, Klaeger S, Phulphagar K, Chea V, Kim N, Vanasse A, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani E, Stevens J, Lane W, Camp S, Meli K, Pappalardi M, Herbert Z, Qiu X, Cejas P, Long H, Shukla S, Van Allen E, Choueiri T, Churchman L, Abelin J, Gurer C, MacBeath G, Childs R, Carr S, Keskin D, Wu C, Kaelin W. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 2025 PMID: 40023154, DOI: 10.1016/j.cell.2025.01.046.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discovery 2025, of1-of21. PMID: 39992403, DOI: 10.1158/2159-8290.cd-24-0991.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Abusive Head Trauma in Infants and Children: Technical Report.Narang S, Haney S, Duhaime A, Martin J, Binenbaum G, de Alba Campomanes A, Barth R, Bertocci G, Care M, McGuone D, Laskey A, Asnes A, Brown V, Girardet R, Heavilin N, Kissoon N, McGregory K, Morgan P, Rosado N, Flaherty E, Sirotnak A, Haney S, Gavril A, Hoffert Gilmartin A, Idzerda S, Messner S, Legano L, Mohr B, Moles R, Palusci V, Nienow S, Budzak A, Suh D, Yoo S, Dumitrescu A, Fredrick D, Gise R, Strominger M, Rubin S, Karr D, Nischal K, Roarty J, Otero H, Milla S, Mercado-Deane M, Alazraki A, Annam A, Benya E, Acharya P, Brown B, Barton K, Daugherty R, Albert G, Bauer D, Ducis K, Lam S, Martin J, Rocque B, Aldana P, Brockmeyer D, Duhaime A, Jea A, Otero H, Milla S, Mercado-Deane M, Alazraki A, Annam A, Benya E, Acharya P, Brown B, Barton K, Daugherty R, Albert G, Bauer D, Ducis K, Lam S, Martin J, Rocque B, Aldana P, Brockmeyer D, Duhaime A, Jea A. Abusive Head Trauma in Infants and Children: Technical Report. Pediatrics 2025, 155 PMID: 39992695, DOI: 10.1542/peds.2024-070457.

  
• Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations that Overcome it's Feedback Inhibition of RAC1 and Migration.Gadal S, Boyer J, Roy S, Outmezguine N, Sharma M, Li H, Fan N, Chan E, Romin Y, Barlas A, Chang Q, Pancholi P, Timaul N, Overholtzer M, Yaeger R, Manova-Todorova K, de Stanchina E, Bosenberg M, Rosen N. Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations that Overcome it's Feedback Inhibition of RAC1 and Migration. Cancer Research 2025 PMID: 39992718, DOI: 10.1158/0008-5472.can-24-2220.

  
• The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer PatientsAntonios J, Adenu-Mensah N, Theriault B, Millares-Chavez M, Huttner A, Aboian M, Chiang V. The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients. Clinical And Translational Neuroscience 2025, 9: 10. DOI: 10.3390/ctn9010010.
• Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapyShaw R, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Guru Murthy G, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Patel A. Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances 2025 PMID: 39969200, DOI: 10.1182/bloodadvances.2024015712.

  
• Enhanced paracrine action of FGF21 in stromal cells delays thymic agingYoum Y, Gliniak C, Zhang Y, Dlugos T, Scherer P, Dixit V. Enhanced paracrine action of FGF21 in stromal cells delays thymic aging. Nature Aging 2025, 1-12. PMID: 39972172, DOI: 10.1038/s43587-025-00813-5.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesisNair R, Vu A, Freer A, Bhatia K, Wang D, Savani M, Matulis S, Lonial S, Jaye D, Boise L, Seo S, Corson T, Nooka A, Bhatt S, McBrayer S, Gupta V, Hu X, Barwick B, Reddi A, Shanmugam M. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 2025, 145: 732-747. PMID: 39693611, DOI: 10.1182/blood.2024025690.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Gynecologic Cytology and Pap SmearsKrishnamurti U, Mosunjac M, Deftereos G. Gynecologic Cytology and Pap Smears. 2025, 1-53. DOI: 10.1007/978-981-19-7696-4_40-1.
• Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, FloridaRogina B, Anderson R, Lebrasseur N, Curan S, Yousefzadeh M, Ghosh B, Duque G, Howlett S, Austad S, Demuth I, Gerstorf D, Korfhage J, Lombard D, Abadir P, Christensen K, Carey J, Alberts S, Campos F, Palavicini J, Palmer A, Bell J, Basisty N, de Cabo R, Gomes A, Dixit V, Sen P, Baur J, Imai S, Li X, Valdez G, Orr M, Pletcher S, Andersen J, Jones L, Castillo-Azofeida D, Bonaguidi M, Suh Y, Duncan F, Murray A, C W, Burkewitz K, Henne M, Zhou K, Bouhrara M, Benjamini D, Kolind S, Walker K, Reiter D, Dean D, Gorbunova V, Gladyshev V, Palovics R, Niedernhofer L, Fan R, Bueckle A, Hurley J, Esser K, Kapahi P, Sato S, Jiang N, Ashiqueali S, Diaz J, Mishra S, Ralmundo N, Banarjee R, Allsopp R, Reynolds L, Zhang B, Sebastiani P, Monti S, Schork N, Rappaport N. Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida. The Journals Of Gerontology Series A 2025, glaf026. PMID: 39932386, DOI: 10.1093/gerona/glaf026.

  
• Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.Dizman N, Doshi S, Knezevic A, Feinaj A, Sayegh N, Hobeika C, Alaghehbandan R, Rives H, Zengin Z, Braun D, Zibelman M, McGregor B, Hammers H, Ged Y, Ornstein M, Msaouel P, Hahn A, Voss M. Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study. Journal Of Clinical Oncology 2025, 43: 503-503. DOI: 10.1200/jco.2025.43.5_suppl.503.
• A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).Saad E, El Ahmar N, Simsek B, Jegede O, Matar S, Mohanna R, Yekeduz E, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Van Allen E, Choueiri T, Atkins M, Signoretti S, Braun D. A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2025, 43: 591-591. DOI: 10.1200/jco.2025.43.5_suppl.591.
• INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).Motzer R, Braun D, Powles T, Gurney H, Fong L, George D, Haas N, McDermott D, Shuch B, Meehan R, Posadas T, Wu S, Elfiky A, Choueiri T. INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: tps610-tps610. DOI: 10.1200/jco.2025.43.5_suppl.tps610.
• Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.Albiges L, Motzer R, Trevino S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Arranz Arija J, Tykodi S, Ma H, Zhou L, Van Kooten Losio M, Simmons A, Rangwala F, Braun D, Choueiri T, Powles T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. Journal Of Clinical Oncology 2025, 43: 438-438. DOI: 10.1200/jco.2025.43.5_suppl.438.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).Kashima S, Xu W, Canniff J, Saliby R, Sun M, Lee G, Machaalani M, Signoretti S, McGregor B, McKay R, Choueiri T, Braun D. Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 562-562. DOI: 10.1200/jco.2025.43.5_suppl.562.
• Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.
• Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).Madsen K, Labaki C, Saad E, Alchoueiry M, Bi K, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Heng D, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC). Journal Of Clinical Oncology 2025, 43: 583-583. DOI: 10.1200/jco.2025.43.5_suppl.583.
• Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.Mohanna R, Simsek B, El Ahmar N, Jegede O, Matar S, Paul M, Nabil Laimon Y, Roberti De Oliveira G, Delcea A, Choueiri T, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial. Journal Of Clinical Oncology 2025, 43: 590-590. DOI: 10.1200/jco.2025.43.5_suppl.590.
• Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate BiopsiesChen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, Sprenkle P, Justice A, Arora S, Weinreb J, Spektor M, Huber S, Humphrey P, Levi A, Staib L, Venkataraman R, Martin D, Onofrey J. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. European Urology Oncology 2025 PMID: 39924390, DOI: 10.1016/j.euo.2025.01.005.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialCecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso P. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025, 131: e35755. PMID: 39917990, DOI: 10.1002/cncr.35755.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Atypical bullous systemic lupus erythematosus with features of linear IgA bullous dermatosisJiang R, Zhou A, Ko C, Girardi M, Hanly A, Xie C, Preda-Naumescu A, Gehlhausen J, Tomayko M. Atypical bullous systemic lupus erythematosus with features of linear IgA bullous dermatosis. JAAD Case Reports 2025, 58: 74-76. PMID: 40129457, PMCID: PMC11930652, DOI: 10.1016/j.jdcr.2024.12.040.

  
• Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500.Appleman V, Matsuda A, Ganno M, Zhang D, Rosentrater E, Maldonado Lopez A, Porciuncula A, Hatten T, Christensen C, Merrigan S, Lee H, Lee M, Wang C, Dong L, Huang J, Iartchouk N, Wang J, Xu H, Yoneyama T, Piatkov K, Haridas S, Harbison C, Gregory R, Parent A, Lineberry N, Arendt C, Schalper K, Abu-Yousif A. Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500. Cancer Immunology Research 2025 PMID: 39918395, DOI: 10.1158/2326-6066.cir-24-0103.
• Autosomal dominant SLURP1 variants cause palmoplantar keratoderma and progressive symmetric erythrokeratodermaJiang X, Mortlock R, Lomakin I, Zhou J, Hu R, Cossio M, Bunick C, Choate K. Autosomal dominant SLURP1 variants cause palmoplantar keratoderma and progressive symmetric erythrokeratoderma. British Journal Of Dermatology 2025, ljaf049. PMID: 39913669, DOI: 10.1093/bjd/ljaf049.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio
• Exploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain InjuryWachtler N, O’Brien R, Ehrlich B, McGuone D. Exploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury. Pharmaceuticals 2025, 18: 223. PMID: 40006037, PMCID: PMC11859800, DOI: 10.3390/ph18020223.
• Distinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease ActivitySánchez-Zuno G, Bucala R, Hernández-Bello J, Palafox-Sánchez C, Vizcaíno-Quirarte A, Muñoz-Valle J. Distinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity. Journal Of Interferon & Cytokine Research 2025, 45: 99-106. PMID: 39914814, DOI: 10.1089/jir.2024.0184.
• Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myelomaPotdar S, Kapadia S, Azeem M, Radzievski R, Lakhani K, Joseph N, Kaufman J, Hofmeister C, Gupta V, Lonial S, Nooka A, Dhodapkar K, Dhodapkar M. Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma. Blood Advances 2025 PMID: 39913930, DOI: 10.1182/bloodadvances.2024015680.

  
• A neoantigen vaccine generates antitumour immunity in renal cell carcinomaBraun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, Vanasse A, Forman C, Forman J, Afeyan A, Schindler N, Liu Y, Li S, Southard J, Chang S, Hirsch M, LeBoeuf N, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen C, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard A, Iorgulescu J, Shim B, Simon J, Signoretti S, Aster J, Elagina L, Carr S, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen L, Oliveira G, Neuberg D, Livak K, Shukla S, Fritsch E, Wu C, Keskin D, Ott P, Choueiri T. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 2025, 639: 474-482. PMID: 39910301, PMCID: PMC11903305, DOI: 10.1038/s41586-024-08507-5.

  8

  

  8 Total citations

  8 Recent citations

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Abstract 76: Characterization of the Cerebral Aneurysm Microenvironment Using Spatial MultiomicsBarak T, Gultekin B, Kilic D, Avsar T, Miyagishima D, Kivrak C, Peksen A, Gutierrez A, Karadag C, Yalcin K, Ercan-Sencicek A, McGuone D, Bayri Y, Kilic T, Gunel M. Abstract 76: Characterization of the Cerebral Aneurysm Microenvironment Using Spatial Multiomics. Stroke 2025, 56: a76-a76. DOI: 10.1161/str.56.suppl_1.76.
• Decreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndromeShin J, Shin H, Gutierrez A, Yoo N, Par-Young J, Osmani L, Shin M, Sanchez-Lara P, Bucala R, Soffer G, Kang I. Decreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndrome. EBioMedicine 2025, 112: 105578. PMID: 39891996, PMCID: PMC11840234, DOI: 10.1016/j.ebiom.2025.105578.
• BPS2025 - Decoupling the role of DNA on mutant p53 aggregationSteinsaltz M, Levine Z. BPS2025 - Decoupling the role of DNA on mutant p53 aggregation. Biophysical Journal 2025, 124: 410a. DOI: 10.1016/j.bpj.2024.11.2206.
• BPS2025 - Decoupling the role of DNA on mutant p53 aggregationSteinsaltz M, Levine Z. BPS2025 - Decoupling the role of DNA on mutant p53 aggregation. Biophysical Journal 2025, 124: 512a. DOI: 10.1016/j.bpj.2024.11.2691.
• BPS2025 - Concentration-dependent role of apolipoprotein E in amyloid beta clearance by human astrocytesNurmakova K, Levine Z. BPS2025 - Concentration-dependent role of apolipoprotein E in amyloid beta clearance by human astrocytes. Biophysical Journal 2025, 124: 407a-408a. DOI: 10.1016/j.bpj.2024.11.2193.
• A Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS MutationsRiess J, Lara M, Luxardi G, de Rodas M, Shimoda M, Kelly K, Lara P, Beckett L, Monjazeb A, Schalper K, Maverakis E, Gandara D. A Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS Mutations. JTO Clinical And Research Reports 2025, 100806. DOI: 10.1016/j.jtocrr.2025.100806.
• An Injectable Alginate Hydrogel Modified by Collagen and Fibronectin for Better Cellular EnvironmentGao D, Shipman W, Sun Y, Yang W, Mathew A, Beraki L, Glahn J, Kochen A, Kyriakides T, Horsley V, Hsia H. An Injectable Alginate Hydrogel Modified by Collagen and Fibronectin for Better Cellular Environment. ACS Applied Bio Materials 2025, 8: 1675-1683. PMID: 39886738, DOI: 10.1021/acsabm.4c01853.

  
• Age-invariant genes: multi-tissue identification and characterization of murine reference genesGonzález J, Thrush-Evensen K, Meer M, Levine M, Higgins-Chen A. Age-invariant genes: multi-tissue identification and characterization of murine reference genes. Aging 2025, 17: 170-202. PMID: 39888841, PMCID: PMC11810059, DOI: 10.18632/aging.206195.
• Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspectsGonzalez R, Horton R, Zhang X, Graham R, Longacre T, Mehrotra A, Allende D, McHugh K, Shia J, Westerhoff M, Srivastava A, Chen W, Vazzano J, Swanson P, Chatterjee D, Cheema H, Ma C, Mannan R, Chetty R, Nowak K, Serra S, Agostini‐Vulaj D, Kazemimood R, Henn P, Kakar S, Choi W, Adeyi O, Jenkins S, Nagtegaal I. Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects. Histopathology 2025 PMID: 39887413, DOI: 10.1111/his.15412.

  
• Interneuron loss and microglia activation by transcriptome analyses in the basal ganglia of Tourette disorderWang Y, Fasching L, Wu F, Suvakov M, Huttner A, Berretta S, Roberts R, Leckman J, Fernandez T, Abyzov A, Vaccarino F. Interneuron loss and microglia activation by transcriptome analyses in the basal ganglia of Tourette disorder. Biological Psychiatry 2025 PMID: 39892689, DOI: 10.1016/j.biopsych.2024.12.022.

  
• P-1273. Connecting Underserved Communities With Saliva-Based PCR Testing for Respiratory Infection: Insights From A Mobile Lab-In-A-Van PilotChoate B, Sardana R, Fajardo K, Wyllie A, Levi A. P-1273. Connecting Underserved Communities With Saliva-Based PCR Testing for Respiratory Infection: Insights From A Mobile Lab-In-A-Van Pilot. Open Forum Infectious Diseases 2025, 12: ofae631.1454. PMCID: PMC11778523, DOI: 10.1093/ofid/ofae631.1454.
• P-551. The Effects of Antiretroviral Therapy on Immune Activation, Inflammation, Cellular Changes and Clinical Outcomes in Elite ControllersChan E, Zhou L, Emu B, Paintsil E, Barakat L. P-551. The Effects of Antiretroviral Therapy on Immune Activation, Inflammation, Cellular Changes and Clinical Outcomes in Elite Controllers. Open Forum Infectious Diseases 2025, 12: ofae631.750. PMCID: PMC11777457, DOI: 10.1093/ofid/ofae631.750.
• P-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline CharacteristicsKumar P, Rolle C, Emu B, Henry Z, Martorell C, McKinnon J, Slim J, Cash R, Anstett K. P-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics. Open Forum Infectious Diseases 2025, 12: ofae631.763. PMCID: PMC11778372, DOI: 10.1093/ofid/ofae631.763.
• Fine‐Needle Aspiration Biopsy of Adrenal Gland Lesions: The Roles of Image Guidance, Rapid On‐Site Evaluation and Additional Tissue SamplingYu S, Dolezal D, Aslanian H, Cai G. Fine‐Needle Aspiration Biopsy of Adrenal Gland Lesions: The Roles of Image Guidance, Rapid On‐Site Evaluation and Additional Tissue Sampling. Cytopathology 2025 PMID: 39878416, DOI: 10.1111/cyt.13472.

  
• Damage sensing through TLR9 regulates inflammatory and antiviral responses during influenza infectionKim J, Yuan Y, Agaronyan K, Zhao A, Wang V, Gau D, Toosi N, Gupta G, Essayas H, Kaminski A, McGovern J, Yu S, Woo S, Lee C, Gandhi S, Saber T, Saleh T, Hu B, Sun Y, Ishikawa G, Bain W, Evankovich J, Chen L, Yun H, Herzog E, Dela Cruz C, Ryu C, Sharma L. Damage sensing through TLR9 regulates inflammatory and antiviral responses during influenza infection. Mucosal Immunology 2025 PMID: 39884393, DOI: 10.1016/j.mucimm.2025.01.008.
• Age-invariant genes: multi-tissue identification and characterization of murine reference genesGonzález J, Thrush-Evensen K, Meer M, Levine M, Higgins-Chen A. Age-invariant genes: multi-tissue identification and characterization of murine reference genes. Aging 2025, 17: 170-202. PMID: 39873648, PMCID: PMC11810070, DOI: 10.18632/aging.206192.

  
• The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort studyHuelsboemer L, Hosseini H, Klimitz F, Diatta F, Boroumand S, O'Brien C, Parikh N, Stögner V, Formica R, Ko C, Azzi J, Draper E, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2025, 103: 286-296. PMID: 40043533, DOI: 10.1016/j.bjps.2025.01.028.
• Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional RegistryMcKay G, Coromilas A, Liu L, Shaw K, Murphy M, Punyamurthy N, Soltero K, Damsky W, Wanat K, Charrow A, Rosenbach M, Caplan A, LaSenna C, Arkin L, Shields B. Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry. JEADV Clinical Practice 2025 DOI: 10.1002/jvc2.615.

  
• Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypesPareja F, Bhargava R, Borges V, Brogi E, Canas Marques R, Cardoso F, Desmedt C, Harigopal M, Lakhani S, Lee A, Leone J, Linden H, Lord C, Marchio C, Merajver S, Rakha E, Reis-Filho J, Richardson A, Sawyer E, Schedin P, Schwartz C, Tutt A, Ueno N, Vincent-Salomon A, Weigelt B, Wen Y, Schnitt S, Oesterreich S. Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes. Npj Breast Cancer 2025, 11: 6. PMID: 39856067, PMCID: PMC11760369, DOI: 10.1038/s41523-025-00719-w.